Skip to main content

Table 1 Patient baseline demographics and clinical characteristics a

From: Peripheral blood CD4+CD25+CD127low regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response

Patient characteristics, N= 39 Mean ± SD or n (%) Median (IQR)
Age, yr 54.8 ± 13.3 56 (44 to 63)
Female, n (%) 35 (89.7)
Disease duration, yr 4.7 ± 3.3 4.5 (1.7 to 8.0)
SJC (range, 0 to 28) 5.8 ± 3.8 5 (3 to 7)
TJC (range, 0 to 28) 5.0 ± 3.5 4 (3 to 6)
Pt-VAS (score/100 mm) 46.2 ± 24.5 45 (30 to 63)
D-VAS (score/100 mm) 42.3 ± 16.7 39 (32 to 54)
CDAI score 19.6 ± 9.3 17.5 (12.0 to 25.2)
SDAI score 21.1 ± 9.9 19.8 (13.4 to 26.9)
HAQ-DI score 1.0 ± 0.7 1 (0.5 to 1.5)
CRP, mg/dl 1.4 ± 1.6 0.7 (0.2 to 2.2)
ESR, mm/h 48.1 ± 32.0 46 (19 to 68)
MMP-3, ng/ml 158.5 ± 147.7 100.2 (60.0 to 221.0)
RF-positive, n (%) 33 (84.6)
ACPA-positive, n (%) 33 (84.6)
Concomitant methotrexate, n (%), dose,b mg/wk 12 (30.8), 8.0 ± 1.2 –, 8.0 (7.6 to 8.0)
Concomitant glucocorticoid, n (%), dose,b mg/day 10 (25.6), 5.1 ± 2.8 –, 5 (3 to 5)
  1. aACPA, Anticitrullinated protein antibody; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; D-VAS, Doctor’s visual analogue scale; ESR, Erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; MMP-3, Matrix metalloproteinase-3; Pt-VAS, Patient’s visual analogue scale; RF, Rheumatoid factor; SDAI, Simplified Disease Activity Index; SJC, Swollen joint count; TJC, Tender joint count. bMean ± standard deviation (SD) and median (interquartile range (IQR)) among patients receiving drugs.
\